TABLE 2

Characteristics of study asthma participants as T2-high and T2-low

T2-highSubjects nT2-lowSubjects np-value
Age years46.8±15.13845.2±13.6650.52
Female n (%)13 (38.0)3840 (61.5)650.01
BMI kg·m−227.6±5.63829.7±6.2650.11
Atopy n (%)27 (84.4)3247 (78.3)600.67
Total IgE IU·mL−1171 (316.5)3885.2 (243.9)640.04
Current smokers n (%)3 (7.9)383 (4.6)650.60
Ex-smokers n (%)9 (23.7)3817 (26.2)651.0
On inhaled corticosteroids n (%)27 (71.1)3847 (75.8)620.64
On oral corticosteroids n (%)15 (40.5)3713 (21.3)610.069
Anti IgE therapy n (%)2 (5.2)383 (4.6)651.0
FEV1 % predicted71.2 (34.1)3888.7 (24.7)650.06
FEV1/FVC %66.5 (21.5)3769.4 (16.6)650.11
FVC % predicted91.8 (16.6)3899.5 (28.7)650.13
FEV1 % increase post-salbutamol12.34 (13.5)377.3 (10.1)640.02
FeNO ppb46.0 (45.5)3621.0 (19.0)620.003
Exacerbations1.5 (3.75)381.0 (2)640.24
Nasal polyps diagnosed n (%)11 (31.4)3516 (26.6)600.79
ACQ51.9±0.9331.4±1.1540.01
Blood eosinophils cells·μL−1285 (215)38200 (200)650.001
Blood neutrophils cells·μL−14370 (3565)384100 (2300)650.59
Sputum eosinophils %4.64 (19.1)190.48 (1.1)250.001
Sputum neutrophils %52.3 (29.9)1249.8 (33.9)150.44
Sputum lymphocytes %0.92 (1.0)191.29 (1.1)240.034
Sputum macrophages %27.6 (32.9)1945.1 (30.0)240.016
Serum CCL18 pg·mL−1170.3 (73.7)33127.2 (96.2)560.03
Serum IL-17A pg·mL−10.28 (0.17)330.32 (0.25)550.17
Serum periostin ng·mL−146.7 (19.2)3345.4 (12.0)550.38
Serum IL-1α pg·mL−136.2 (9.6)3832.9 (9.6)640.009
Plasma CCL11 pg·mL−1106.26 (40.83)3594.82 (57.40)580.02
Plasma CCL26 pg·mL−123.3 (15.8)3513.9 (16.9)580.002

Data are presented as mean±sd or median (interquartile range), unless otherwise stated. BMI: body mass index; FEV1: forced expiratory volume in 1s; FVC: forced vital capacity; FeNO: exhaled nitric oxide fraction; ACQ5: 5-item asthma control questionnaire; IL: interleukin.